Risk factor
Very poor trading liquidity
Profitability factor
Very favourable analyst view
About
MPH Health Care AG, an investment company, engages in the healthcare business in Germany. It produces and sells medicinal products for the therapies of cancer, HIV, and other chronic diseases. The company also offers medical aesthetic treatments; and develops and sells pharmaceutical and medical products; and provides related services, as well as medical devices for the aesthetic surgery and cosmetic dermatology. In addition, it is involved in the provision of cytostatic solutions; and real estate activities. The company was formerly known as MPH Mittelständische Pharma Holding AG and changed its name to MPH Health Care AG in 2017. The company was founded in 2008 and is based in Berlin, Germany. MPH Health Care AG is a subsidiary of Magnum AG.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, ove
Target Price
The average target price of 93M1.DE is 37 and suggests 91% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell